GO:0005164 tumor necrosis factor receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005164 (tumor necrosis factor receptor binding) is a molecular function defined as binding to a tumor necrosis factor receptor.
• This activity is mediated by ligands and engineered binders such as TNF superfamily cytokines, aptamers, nanobodies, and designed antagonists or agonists.
• TNF receptor binding initiates signaling through receptor trimerization and recruitment of adaptors including TRAFs.
• Dysregulated TNF receptor binding contributes to inflammatory bowel disease, autoinflammatory syndromes, and cancer.
• The function can be studied with binding assays, structural modeling, and CRISPR-engineered cell models.
• EDITGENE provides knockout, point-mutation, knock-in, overexpression, and library screening services to dissect TNF receptor binding mechanisms.
Description
GO:0005164 tumor necrosis factor receptor binding is a molecular function that describes the physical interaction between a protein or ligand and a tumor necrosis factor receptor (TNFR). This activity is central to the initiation of TNFR signaling, which controls inflammation, cell survival, proliferation, and apoptosis. Researchers study this function to understand how cytokines, engineered binders, and pathogenic modifiers engage TNFRs and to develop therapeutics that modulate these interactions. The term is distinct from downstream signaling events; it specifically captures the binding step that precedes receptor activation. Because TNFR binding is a point of therapeutic intervention, it is a major focus in immunology, oncology, and drug discovery.
tumor necrosis factor receptor binding At A Glance
| GO ID | GO:0005164 |
|---|---|
| GO term | tumor necrosis factor receptor binding |
| Ontology | molecular_function |
| Synonym | TNF receptor binding; tumor necrosis factor; tumor necrosis factor receptor ligand |
| Major function | Binding to a tumor necrosis factor receptor, initiating or modulating TNFR signaling |
| Example binders | TNF superfamily ligands, aptamers, nanobodies, designed antagonists/agonists |
| Downstream adaptors | TRAFs and other TNFR-associated factors |
| Disease relevance | Inflammatory bowel disease, autoinflammatory syndromes, cancer |
What Is GO:0005164?
In the Gene Ontology, GO:0005164 tumor necrosis factor receptor binding is defined as the molecular function of binding to a tumor necrosis factor receptor. It is a binding activity, not a catalytic activity, and it is classified under molecular_function. The term is synonymous with TNF receptor binding, tumor necrosis factor, and tumor necrosis factor receptor ligand. This function is performed by ligands, engineered proteins, and other molecules that physically associate with TNFR family members.
Why Is tumor necrosis factor receptor binding Important in Cell Biology?
Tumor necrosis factor receptor binding is important because it is the first committed step in TNFR signaling, which regulates inflammation, immunity, and cell fate. Aberrant binding or signaling is linked to chronic inflammatory diseases and cancer, making this function a prime target for therapeutic antibodies, aptamers, and nanobodies. Understanding the structural and biochemical basis of binding enables rational design of antagonists and agonists with desired clinical profiles.
• Initiates TNFR signaling that controls inflammation and immunity.
• Mediates pro-inflammatory and anti-tumor effects of TNF superfamily cytokines.
• Is targeted by therapeutic aptamers and nanobodies for anti-inflammatory or anti-tumor activity.
• Involves adaptor proteins such as TRAFs that link binding to downstream pathways.
• Is dysregulated in inflammatory bowel disease and autoinflammatory syndromes.
• Can be modulated by environmental toxins that modify ligand cysteines.
• Serves as a model for studying receptor-ligand specificity and affinity.
• Enables design of potent antagonists and agonists using computational methods.
• Provides a basis for CRISPR-based functional genomics of TNFR pathways.
• Supports development of precision therapeutics in oncology and immunology.
Molecular Mechanism of tumor necrosis factor receptor binding
Ligand recognition and receptor engagement
In simple terms: A ligand or binder physically docks onto a TNF receptor.
Tumor necrosis factor receptor binding begins with specific recognition between a ligand or engineered binder and the extracellular domain of a TNFR. This interaction is driven by structural complementarity and can be studied using binding assays in fibroblasts and other cell types. Engineered aptamers and nanobodies can be selected to bind TNFR1 or TNFR2 with high specificity.
Receptor trimerization and conformational change
In simple terms: Binding causes receptors to cluster and change shape.
Upon binding, TNFRs typically trimerize, which is a prerequisite for signaling. This clustering induces conformational changes that expose intracellular domains for adaptor recruitment. Designed antagonists and agonists can modulate this step, as shown by target-conditioned diffusion methods.
Adaptor recruitment and signaling initiation
In simple terms: The clustered receptor recruits helper proteins that start signals.
Trimerized TNFRs recruit adaptor proteins such as TRAFs, which are critical for downstream signaling. This recruitment links receptor binding to activation of NF-kB, MAPK, and cell death pathways. The binding event itself is therefore a key control point for pathway output.
Modulation by chemical modifications
In simple terms: Chemicals can alter the ligand and change binding.
Methylmercury can directly modify cysteine 105 in oncostatin M, promoting its binding to TNFR3 and inhibiting cell growth. This illustrates that post-translational or chemical modifications of ligands can alter TNFR binding specificity and outcomes. Such modifications are relevant to toxicology and environmental health research.
Therapeutic targeting of TNFR binding
In simple terms: Drugs and binders can block or mimic TNFR binding.
Aptamers selected against TNFR1 show anti-inflammatory activity by blocking binding. Nanobody-161 binds TNFR2 to exert anti-tumor effects without blocking TNF-alpha binding, demonstrating that binding can be modulated at distinct sites. Computational design has generated potent TNFR superfamily antagonists and agonists.
Key Genes Involved in GO:0005164 tumor necrosis factor receptor binding
The following genes and proteins are central to tumor necrosis factor receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TNF | Cytokine ligand that binds TNFR1 and TNFR2 | Prototype ligand for studying TNFR binding |
| TNFRSF1A | TNFR1 receptor for TNF | Target of aptamers for anti-inflammatory activity |
| TNFRSF1B | TNFR2 receptor for TNF | Target of nanobody-161 for anti-tumor effects |
| TNFRSF3 | TNFR3 receptor for oncostatin M | Binding modulated by methylmercury modification |
| TRAF1 | Adaptor recruited to TNFR complexes | Links binding to signaling |
| TRAF2 | Adaptor recruited to TNFR complexes | Links binding to NF-kB and MAPK |
| TRAF3 | Adaptor with regulatory roles | Modulates TNFR signaling |
| TRAF4 | Adaptor in TNFR superfamily signaling | Context-dependent regulation |
| TRAF5 | Adaptor in TNFR signaling | Contributes to pathway specificity |
| TRAF6 | Adaptor in TNFR superfamily signaling | Links to immune signaling |
| OSM | Ligand that binds TNFR3 | Modified by methylmercury at Cys105 |
| TNFRSF1A variants | Receptor variants in autoinflammatory disease | Studied in TRAPS |
| TNFRSF1A/B | Receptors in inflammatory bowel disease | Studied in IBD |
| TNF-alpha | Cytokine ligand | Target of anti-TNF therapies |
| TNFR2 | Receptor for anti-tumor targeting | Bound by nanobody-161 |
| TNFR1 | Receptor for anti-inflammatory targeting | Bound by aptamers |
| TNF superfamily ligands | Diverse binders of TNFRs | Engineered antagonists/agonists |
How Is tumor necrosis factor receptor binding Regulated?
Tumor necrosis factor receptor binding is regulated at multiple levels. Ligand availability and post-translational modifications, such as cysteine modification by methylmercury, can alter binding to TNFR3. Receptor expression levels and alternative splicing influence which TNFRs are available for binding. Adaptor proteins like TRAFs provide feedback regulation of signaling after binding. Engineered binders can be designed to compete with or mimic natural ligands, thereby modulating the function.
tumor necrosis factor receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNFRSF1A | TRAPS autoinflammatory syndrome | Knock-in of patient variants in cell lines |
| TNFRSF1A/B | Inflammatory bowel disease | Knockout and overexpression in intestinal epithelial cells |
| TNFRSF1B | Cancer anti-tumor targeting | Overexpression for nanobody-161 binding assays |
| OSM | Methylmercury-induced growth inhibition | Point mutation of Cys105 in OSM |
| TNF | Inflammation and autoimmunity | Knockout in immune cells |
Inflammatory bowel disease
Tumor necrosis factor receptor binding is directly implicated in inflammatory bowel disease, where TNF binding to TNFRs drives chronic inflammation. Studies of TNFR expression and function in IBD support targeting this interaction therapeutically.
TNF receptor-associated periodic syndrome (TRAPS)
TRAPS is an autoinflammatory disease linked to mutations in TNFRSF1A, which affect receptor function and binding. Understanding TNFR binding helps explain the molecular basis of TRAPS and guides treatment.
Cancer
TNFR2 binding by nanobody-161 exerts anti-tumor effects without blocking TNF-alpha binding, highlighting the therapeutic potential of targeting specific TNFR binding events in cancer. Designed antagonists and agonists also show promise in oncology.
Toxicology and growth inhibition
Methylmercury modification of oncostatin M promotes binding to TNFR3 and inhibits cell growth, linking environmental exposure to altered TNFR binding. This has implications for toxicology and cell growth regulation.
From tumor necrosis factor receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TNFR binding affect inflammation? | Knockout of TNFRSF1A or TNFRSF1B in cell lines |
| Does a specific point mutation alter ligand binding? | Point mutation of OSM Cys105 |
| Can a designed binder activate TNFR signaling? | Knock-in of engineered receptor or ligand |
| Where does TNFR binding occur in cells? | Tagged knock-in of TNFR with fluorescent tag |
| Does overexpression of TNFR enhance binding? | Overexpression of TNFRSF1B in cancer cells |
| Which genes regulate TNFR binding? | CRISPR library screening in TNFR-expressing cells |
How to Study the tumor necrosis factor receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Direct ligand-receptor binding | Quantify TNF binding to TNFR |
| Surface plasmon resonance | Binding kinetics and affinity | Characterize engineered binders |
| CRISPR knockout | Gene requirement for binding | Identify essential TNFR pathway genes |
| CRISPR library screening | Genome-wide regulators of binding | Discover novel modulators |
| Nanobody binding assay | Specific TNFR2 binding | Anti-tumor targeting |
| Aptamer selection | TNFR1 binding specificity | Anti-inflammatory activity |
| Mass spectrometry | Ligand modifications | Detect cysteine modifications |
Binding assays
Radioligand or fluorescent binding assays measure direct interaction between ligands and TNFRs, as demonstrated in fibroblasts. These assays quantify affinity and specificity of natural and engineered binders.
Structural and computational modeling
Target-conditioned diffusion and other computational methods generate potent TNFR superfamily antagonists and agonists. Structural modeling helps predict how mutations affect binding.
CRISPR-based functional genomics
CRISPR knockout and library screening can identify genes required for TNFR binding and downstream signaling. These approaches link genotype to binding phenotype.
Antibody and nanobody engineering
Selection of aptamers and nanobodies enables precise targeting of TNFR1 or TNFR2 for anti-inflammatory or anti-tumor effects. These reagents are valuable for probing binding mechanisms.
How CRISPR Can Be Used to Study GO:0005164 tumor necrosis factor receptor binding
Knockout
CRISPR knockout of TNFRSF1A, TNFRSF1B, or TRAF genes can abolish or reduce tumor necrosis factor receptor binding and downstream signaling. These models help determine which receptors and adaptors are required for specific binding events.
Point Mutation
Point mutations, such as OSM Cys105, can be introduced to test how specific residues affect binding to TNFR3. This approach is useful for dissecting structure-function relationships in ligand-receptor interactions.
Knock-in
Knock-in of tagged or variant TNFRs allows visualization and functional analysis of binding in live cells. Patient-derived variants, such as those in TRAPS, can be knocked in to model disease.
Overexpression
Overexpression of TNFRs or ligands enhances binding signals and enables detection of weak interactions. This is particularly useful for screening engineered binders like nanobody-161.
How EDITGENE Supports tumor necrosis factor receptor binding Research
Researchers studying tumor necrosis factor receptor binding-related genes often need to determine whether a candidate gene is causally involved in binding, signaling, or disease. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for tumor necrosis factor receptor binding research.
Frequently Asked Questions About tumor necrosis factor receptor binding
What is GO:0005164 tumor necrosis factor receptor binding?
It is a molecular function defined as binding to a tumor necrosis factor receptor, as described in the Gene Ontology.
What genes are involved in tumor necrosis factor receptor binding?
Key genes include TNF, TNFRSF1A, TNFRSF1B, TNFRSF3, TRAF1-6, and OSM.
How does tumor necrosis factor receptor binding initiate signaling?
Binding induces receptor trimerization and recruitment of adaptors such as TRAFs, leading to downstream signaling.
What diseases are linked to tumor necrosis factor receptor binding?
Inflammatory bowel disease, TRAPS, cancer, and toxicology-related growth inhibition are linked to this function.
Can CRISPR be used to study tumor necrosis factor receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect binding mechanisms.
What are examples of engineered binders for TNFRs?
Aptamers against TNFR1 and nanobody-161 against TNFR2 are examples of engineered binders.
How is tumor necrosis factor receptor binding measured?
Binding assays, surface plasmon resonance, and computational modeling are common methods.
What is the role of TRAFs in TNFR binding?
TRAFs are adaptor proteins recruited after binding to transduce signals.
Can environmental toxins affect TNFR binding?
Yes, methylmercury modifies oncostatin M to promote binding to TNFR3.
What model systems are used to study TNFR binding?
Cell lines with CRISPR knockouts, point mutations, knock-ins, and overexpression are commonly used.
Conclusion
GO:0005164 tumor necrosis factor receptor binding is a fundamental molecular function that initiates TNFR signaling and is implicated in inflammation, autoimmunity, and cancer. Understanding its mechanism, regulation, and disease relevance provides a foundation for therapeutic development. CRISPR-based models and EDITGENE services enable precise functional dissection of this binding activity.
References
- 1. Souza RF et al.. 2023. Study of tumor necrosis factor receptor in the inflammatory bowel disease.. World J Gastroenterol 29(18):2733-2746 PMID: 37274062
- 2. Vilcek J et al.. 1987. Tumor necrosis factor: receptor binding and mitogenic action in fibroblasts.. J Cell Physiol Suppl Suppl 5:57-61 PMID: 2824534
- 3. Glögl M et al.. 2024. Target-conditioned diffusion generates potent TNFR superfamily antagonists and agonists.. Science 386(6726):1154-1161 PMID: 39636970
- 4. Chu X et al.. 2023. Targeting Tumor Necrosis Factor Receptor 1 with Selected Aptamers for Anti-Inflammatory Activity.. ACS Appl Mater Interfaces 15(9):11599-11608 PMID: 36812453
- 5. Bradley JR et al.. 2001. Tumor necrosis factor receptor-associated factors (TRAFs).. Oncogene 20(44):6482-91 PMID: 11607847
- 6. Huang L et al.. 2025. Novel nanobody-161 binds tumor necrosis factor receptor 2 (TNFR2) to exert an anti-tumor effect but does not block TNFα-binding.. Front Immunol 16:1694313 PMID: 41438755
- 7. Toyama T et al.. 2023. Methylmercury directly modifies the 105th cysteine residue in oncostatin M to promote binding to tumor necrosis factor receptor 3 and inhibit cell growth.. Arch Toxicol 97(7):1887-1897 PMID: 37193757
- 8. Li S et al.. 2019. [A family of tumor necrosis factor receptor-associated periodic syndrome].. Zhonghua Er Ke Za Zhi 57(6):477-482 PMID: 31216807
